Medtronic Exclusive Reactive ATP(TM) Therapy Slows Progression of Atrial Fibrillation in Real-World Patient Population
(Thomson Reuters ONE) -
Data Presented as Late Breaking Clinical Trial at EUROPACE 2017
DUBLIN and VIENNA - June 18, 2017 - Continuing its leadership in the detection,
reduction, and treatment of atrial fibrillation (AF), Medtronic plc (NYSE: MDT)
today announced that its Reactive ATP(TM) therapy slows the progression of AF in
patients with implanted cardiac devices. A robust, real-world analysis of nearly
8,800 patients was presented as a late breaking clinical trial at EHRA EUROPACE-
CARDIOSTIM 2017.
An unusually fast or quivering rhythm in the heart's upper chambers (atria), AF
is a progressive disease that afflicts more than 33 million people worldwide.(1)
Common among patients with cardiac devices, AF impairs quality of life, and
increases the risk of hospitalization, stroke and death. Reactive ATP (atrial-
based antitachycardia pacing) is an advanced, painless pacing therapy found
exclusively on Medtronic pacemakers, implantable cardioverter defibrillators
(ICDs) and cardiac resynchronization therapy (CRT) devices. It repeatedly sends
pacing pulses to the atria during abnormally fast rhythms to restore the heart's
normal rhythm, thereby slowing the progression of AF.
The retrospective analysis assessed pacemaker, ICD and CRT device data from
8,798 patients followed by the Medtronic CareLink® remote monitoring system.
Reactive ATP therapy was associated with a statistically significant decrease in
AF events compared to a matched control group. Most notably, the Reactive ATP
patient group experienced a 38 percent reduction in persistent AF events
(lasting greater than seven days) (p<0.0001). This benefit was observed across
patient age, sex, and device type.
"Atrial fibrillation can be a debilitating disease that imposes a significant
burden upon the entire healthcare community - impacting patients, caregivers,
providers and costs of care - especially as the disease progresses," said
Giuseppe Boriani, M.D., Ph.D., full professor of cardiology at the University of
Modena and Reggio Emilia, Italy. "These are the first real-world data on the
clinical impact of Reactive ATP therapy and the first in patients with ICDs and
CRT devices. These data have important implications for all device patients
because of the high prevalence of AF and the correlation of disease progression
to worsened patient outcomes."
This study builds upon the MINERVA trial, the first randomized, controlled study
of Reactive ATP. It found that Reactive ATP therapy significantly slowed AF
disease progression in patients with pacemakers with the therapy, compared to
those without it.(2) Furthermore, Reactive ATP significantly reduced AF-related
hospitalizations, emergency department visits and cardioversions, resulting in
payer cost savings.(2,3 )
"Physicians have been asking how the CareLink Network data can be leveraged to
gain real-world insights into the benefits of our therapies," said Rob Kowal,
M.D., Ph.D., vice president and chief medical officer of the Cardiac Rhythm and
Heart Failure Division at Medtronic. "This study does exactly that. It helps us
understand how Reactive ATP impacts the burden of persistent atrial fibrillation
in a larger and more varied group of patients than we might normally be able to
study within the constraints of a controlled trial."
In collaboration with leading clinicians, researchers and scientists worldwide,
Medtronic offers the broadest range of innovative medical technology for the
interventional and surgical treatment of cardiovascular disease and cardiac
arrhythmias. The company strives to offer products and services of the highest
quality that deliver clinical and economic value to healthcare consumers and
providers around the world.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among
the world's largest medical technology, services and solutions companies -
alleviating pain, restoring health and extending life for millions of people
around the world. Medtronic employs more than 88,000 people worldwide, serving
physicians, hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as
those described in Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from anticipated
results.
-end-
(1) Chugh S, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial
fibrillation: a global burden of disease 2010 study. Circulation.
2014; 129:837-847.
(2) Padeletti, L., Pürerfellner, H., Mont, L. et al. New-generation atrial
antitachycardia pacing (Reactive ATP) is associated with reduced risk of
persistent or permanent atrial fibrillation in patients with bradycardia:
Results from the MINERVA randomized multicenter international trial. Heart
Rhythm. 2015;12:1717-1725.
(3) Boriani G, Manolis AS, Tukkie R et al. Effects of enhanced pacing modalities
on health care resource utilization and costs in bradycardia patients: An
analysis of the randomized MINERVA trial. Heart Rhythm 2015;12:1192-200.
Contacts:
Tracy McNulty
Public Relations
+1-763-526-2492
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medtronic plc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 18.06.2017 - 15:00 Uhr
Sprache: Deutsch
News-ID 548450
Anzahl Zeichen: 6331
contact information:
Town:
Dublin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 474 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medtronic Exclusive Reactive ATP(TM) Therapy Slows Progression of Atrial Fibrillation in Real-World Patient Population"
steht unter der journalistisch-redaktionellen Verantwortung von
Medtronic plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
